Looking into this for someone else

Someone you care about is unwell, and you want to be useful. You can look through what’s recruiting in Canada, keep what seems worth a second look, and send it to them or their doctor in one message.

Whether they follow any of it up is theirs to decide.

A Care Package is a note you put together

As you look, keep the trials that seem worth a second look. When you’re ready, they go to the person you’re thinking of — or to their doctor — as one plain-language note, in your words. Nothing is sent until you say so.

  1. LookBrowse what’s recruiting in Canada.
  2. KeepSave the ones worth a second look.
  3. SendOne note, in your words, when you’re ready.

Whether they read it, or do anything with it, is entirely theirs. You don’t need their details to do any of this.

Not sure how to bring it up? A few things worth knowing first →

RecruitingDrugDeviceBehavioralOlder adultsHealthy volunteers
Prostate Cancer →

36 trials matching “Prostate Cancer” · showing 30

Comparing 3 approaches for metastatic castration-resistant prostate cancer (mcrpc)

Explore this study →

There are 3 groups in this study. Group A receives INR731, together with one or more of: Androgen deprivation therapy (ADT). Group B receives INR731 and Enzalutamide, together with one or more of: Androgen deprivation therapy (ADT). Group C receives INR731 and Abiraterone, together with one or more of: Androgen deprivation therapy (ADT).

Sites in Montreal and Toronto

  • Phase 1
  • 3 groups
  • Sites in Toronto and Montreal
  • Recruiting

Official title: A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC) · Novartis Pharmaceuticals

Comparing Opevesostat with Abiraterone acetate for metastatic castration-resistant prostate cancer (mcrpc)

Explore this study →

There are 2 groups in this study. Group A receives Opevesostat, together with one or more of: Dexamethasone, Fludrocortisone acetate and Hydrocortisone. Group B, the comparison group, receives one or more of: Abiraterone acetate, Prednisone acetate and Enzalutamide.

Sites in Abbotsford British Columbia, Edmonton and 5 more cities

  • Phase 3
  • 2 groups
  • Sites in Edmonton, Abbotsford British Columbia and 5 more cities
  • Recruiting

Official title: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC) · Merck Sharp & Dohme LLC

Testing Saruparib against a placebo for prostate cancer

Explore this study →

There are 4 groups in this study. Group A receives Saruparib, together with one or more of: Androgen Deprivation Therapy (ADT). Group B, the placebo group, receives Placebo, together with one or more of: Androgen Deprivation Therapy (ADT). Group C receives Saruparib, together with one or more of: Abiraterone + Prednisolone/Prednisone and Androgen Deprivation Therapy (ADT). …and 1 more groups.

Sites in Toronto, Abbotsford British Columbia and 8 more cities

  • Phase 3
  • 4 groups
  • Sites in Calgary, Abbotsford British Columbia and 8 more cities
  • Recruiting

Official title: A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Prostate Cancer · AstraZeneca

Comparing 10 approaches for progressive metastatic castrate resistant prostate cancer

Explore this study →

There are 10 groups in this study. Group A receives one or more of: Tulmimetostat DL1 QD and JSB462 Dose 1 QD. Group B receives one or more of: Tulmimetostat DL1 QD and JSB462 Dose 2 QD. Group C receives one or more of: Tulmimetostat DL2 QD and JSB462 Dose 1 QD. …and 6 more groups.

One site, in Halifax

  • Phase 1
  • 10 groups
  • One site, in Halifax
  • Recruiting

Official title: An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Progressive Metastatic Castrate Resistant Prostate Cancer · Novartis Pharmaceuticals

Comparing 5 approaches for metastatic hormone-sensitive prostate cancer (mhspc)

Explore this study →

There are 5 groups in this study. Groups A, C and D receive one or more of: Tulmimetostat, Darolutamide and Androgen Deprivation Therapy (ADT). Group B receives one or more of: Tulmimetostat, Abiraterone, Prednisone/Prednisolone and Androgen Deprivation Therapy (ADT). Group E, the comparison group, receives one or more of: Darolutamide and Androgen Deprivation Therapy (ADT).

One site, in Montreal

  • Phase 1
  • 5 groups
  • One site, in Montreal
  • Recruiting

Official title: TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) · Novartis Pharmaceuticals

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Concord provides information only. Trial listings come from public registries, and whether anyone can take part is decided by the trial site and their own care team.